BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%

BriaCell Therapeutics Corp. (CVE:BCTGet Rating) shares were down 3.8% on Friday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.

BriaCell Therapeutics Price Performance

The firm’s 50-day moving average is C$10.60 and its two-hundred day moving average is C$10.60. The company has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68.

Insider Buying and Selling

In other BriaCell Therapeutics news, Director William Williams purchased 27,272 shares of BriaCell Therapeutics stock in a transaction that occurred on Thursday, July 14th. The shares were bought at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the completion of the transaction, the director now owns 27,272 shares of the company’s stock, valued at approximately C$97,497.40.

BriaCell Therapeutics Company Profile

(Get Rating)

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

Featured Articles

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.